Abstract:Many phosphorescent iridium complexes are potent candidates as photodynamic therapeutic agents. In this work, a series of mixed-ligand phosphorescent iridium complexes (Ir1: [Ir(L-1)(bpy)Cl](PF6)(2); Ir2: [Ir(L-1)(ppy)Cl](PF6); Ir3: [Ir(L-2)(bpy)Cl](PF6)(2); Ir4: [Ir(L-2)(ppy)Cl](P(F)6). L1 = 2,6-bis(2-benzimidazolyl) pyridine; bpy = 2,2'-bipyridine; L-2 = 2,6-bis(1-methyl-benzimidazol-2-yl)pyridine; ppy = 2-phenylpyridine) have been synthesized and characterized. These complexes display high luminescence quantum yields and long phosphorescence lifetimes. All the complexes are resistant to hydrolysis in aqueous solutions, and can produce singlet oxygen (O-1(2)) effectively upon irradiation. Ir1 and Ir2 show pH-sensitive emission properties. Interestingly, higher cellular uptake efficiency is observed for Ir2 and Ir4 with the cyclometalated ppy ligand in human lung adenocarcinoma A549 cells. Ir2 with pH-sensitive emission properties can selectively image lysosomes, and Ir4 can specifically target mitochondria. Both Ir2 and Ir4 exhibit potent photodynamic therapy (PDT) effects, with Ir2 displaying a higher phototoxicity index (PI) especially in A549 cells (PI > 54). Mechanism studies indicate that Ir2 and Ir4 can induce apoptosis through reactive oxygen species (ROS) generation and caspase activation upon visible light (425 nm) irradiation. As expected, Ir2 can damage lysosomes more effectively with a pH-sensitive singlet oxygen (O-1(2)) yield, while Ir4 tends to impair mitochondrial function. Nevertheless, the practical application of Ir2 and Ir4 for PDT may be limited to superficial tumors due to the short excitation wavelength (425 nm). Our study gives insights into the design and anticancer mechanisms of new metal-based PDT anticancer agents.

Cyclometalated Iridium(iii) Complexes As Lysosome-Targeted Photodynamic Anticancer and Real-Time Tracking Agents

ridium(III) complexes as lysosome- targeted photodynamic anticancer and real-time tracking agents†

Cyclometalated Ir(III) Complexes as Lysosome-Targeted Photodynamic Anticancer Agents

Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

Dual Functions of Cyclometalated Iridium(III) Complexes: Anti-Metastasis and Lysosome-Damaged Photodynamic Therapy.

Cyclometalated Iridium(iii) Complexes for Mitochondria-Targeted Combined Chemo-Photodynamic Therapy.

Lysosome-targeted Cyclometalated Ir(III) Complexes as Photosensitizer/Photoredox Catalysis for Cancer Therapy

Cyclometalated iridium(iii) N-heterocyclic carbene complexes as potential mitochondrial anticancer and photodynamic agents.

Cyclometalated Ir(III) Complexes As Targeted Theranostic Anticancer Therapeutics: Combining HDAC Inhibition with Photodynamic Therapy.

Iridium(iii) complexes with five-membered heterocyclic ligands for combined photodynamic therapy and photoactivated chemotherapy.

Phosphorescent Iridium(iii)-Bis-n-heterocyclic Carbene Complexes As Mitochondria-Targeted Theranostic and Photodynamic Anticancer Agents.

Mitochondria-targeted Phosphorescent Cyclometalated Iridium(iii) Complexes: Synthesis, Characterization, and Anticancer Properties

Synthesis, Photophysical and Anticancer Properties of Mitochondria-Targeted Phosphorescent Cyclometalated Iridium(iii) N-heterocyclic Carbene Complexes.

Mixed-ligand iridium(iii) complexes as photodynamic anticancer agents.

Cyclometalated iridium(iii) complex nanoparticles for mitochondria-targeted photodynamic therapy

Bichromophoric Anticancer Drug: Targeting Lysosome with Rhodamine Modified Cyclometalated Iridium(III) Complexes

Novel Lysosome-Targeted Cyclometalated Iridium(III) Anticancer Complexes Containing Imine-N-heterocyclic Carbene Ligands: Synthesis, Spectroscopic Properties and Biological Activity

Lysosome-Targeted Cyclometalated Iridium (Iii) Anticancer Complexes Bearing Phosphine-Sulfonate Ligands

A Cyclometallated Iridium(iii) Complex with Multi-Photon Absorption Properties As an Imaging-Guided Photosensitizer.

Biotin-modified Cyclometalated Iridium-Based Photosensitizers As Mitochondria-Targeted Theranostic Agents for Tumor Photodynamic Therapy in Vitro and in Vivo

Synthesis of Ph-Responsive Cyclometalated Iridium(iii) Complex and Its Application in the Selective Killing of Cancerous Cells